Wyeth and Santaris Pharma to collaborate on RNA-based medicines



If you want to attain a good health, then simply you have to spend your precious time and will have to do some hard work. Without working hard, you cannot get a healthy body. Especially those people who are fat and want to reduce their weight must follow a specific plan so that they can

Full Post: Useful tips to make the body healthy and fit

Wyeth Pharmaceuticals, a division of Wyeth, and Santaris Pharma have announced that the companies have entered into a worldwide strategic alliance to discover, develop and commercialize new medicines based on Santaris Pharma’s proprietary Locked Nucleic Acid (LNA) drug platform, which allows specific targeting and regulation of microRNAs (miRNAs) and messenger RNAs (mRNAs) as a means to affect gene expression mediated by the targeted RNAs.

Under the terms of the agreement, Santaris Pharma will receive an upfront payment of $7 million in cash and Wyeth will make a $10 million equity investment in Santaris Pharma. Santaris Pharma may receive further milestone payments of up to $83 million for each of 10 potential targets. In addition, Santaris Pharma would receive royalties on the worldwide sales of all products arising from the alliance. The term of the research portion of the collaboration is three years. Wyeth has the right to extend the research portion up to two additional years.

Wyeth will select the RNA targets against which Santaris Pharma will use their proprietary LNA drug platform to generate unique drug candidates. Wyeth will be responsible for the development and commercialization of products arising from the alliance.

“With this alliance Wyeth explores a fourth platform technology targeting RNAs, which complements our expertise in small molecules, vaccines and protein-based therapeutics,” says Mikael Dolsten, President, Wyeth Research. “This will increase our ability to develop and bring to market innovative, high-value medicines that have the potential to address significant unmet needs in critical therapeutic areas.”

“We are delighted to welcome Wyeth as a new major partner,” says Soren Tulstrup, President and CEO of Santaris Pharma. “This strategic alliance further consolidates Santaris Pharma’s leading position in the rapidly evolving RNA-based therapeutic field. The scope of this collaboration demonstrates the utility of Santaris Pharma’s proprietary LNA Drug Platform for developing new therapies targeting RNAs.”

About the Locked Nucleic Acid Drug Platform

There are two major classes of RNA targets for this collaboration. messengerRNAs and microRNAs. miRNAs are recognized as important elements in regulation of gene expression in both normal and diseased cells, whereas mRNAs are translated into the proteins that determine all aspects of cell identity and behavior. Santaris Pharma’s proprietary technology allows for the discovery of molecules that specifically and potently inhibit the function of either of these classes of RNA.

The Locked Nucleic Acid-based technology developed by Santaris Pharma creates synthetic chemical versions (LNAs) of the normal nucleic acid building blocks of RNAs. These LNAs improve the drug-like qualities of resulting therapeutics, called oligonucleotides, by increasing resistance to metabolism, increasing half-life and improving tissue uptake. The LNA-based therapeutics also demonstrate improved binding affinity to their target RNA, which increases potency many-fold over other nucleotide therapeutics.

http://www.wyeth.com/

Link




Santaris Pharma announced today that SPC3042, a RNA-based antisense oligonucleotide developed using the company’s proprietary Locked Nucleic Acid (LNA) technology, potently blocks survivin, a key survival protein in cancer cells, in both in vitro and in vivo models of prostate cancer. Importantly, SPC3042 works synergistically with the anticancer drug paclitaxel (Taxol) in both model systems.

Full Post: Santaris Pharma releases positive data on LNA-based survivin inhibitor



FORMA Therapeutics has announced that it has entered into a license and option agreement through the Novartis Option Fund. Under the terms of the agreement, FORMA will leverage its transformative biology and chemistry platform to develop inhibitors for an undisclosed protein-protein interaction target in the field of oncology. The agreement includes an upfront fee and

Full Post: FORMA Therapeutics to collaborate with Novartis on inhibitors



MorphoSys AG and Galapagos NV announced today the launch of a long term co-development alliance aimed at discovering and developing antibody therapies based on novel modes of action in bone and joint disease, including rheumatoid arthritis, osteoporosis and osteoarthritis. The alliance spans all activities from target discovery through to completion of proof of concept clinical

Full Post: MorphoSys and Galapagos enter alliance to co-develop novel therapeutic antibodies in bone and joint disease



Synerx Pharma, LLC has announced the submission to the FDA of Isosulfan Blue Injection (generic equivalent to Lymphazurin, Covidien (formerly US Surgical)). This ANDA submission is the culmination of a four year joint effort by Synerx Pharma, LLC and its exclusive raw material supplier Apicore, LLC. According to Synerx Pharma and Apicore, the active ingredient

Full Post: Synerx Pharma announces FDA submission of Isosulfan Blue injection ANDA



Sun Pharmaceutical Industries Ltd. has announced that its fully owned US subsidiary, Sun Pharmaceutical Industries, Inc., has acquired 100% ownership of Chattem Chemicals, Inc. (Chattem) from Elcat, Inc,. The terms of the transaction were not disclosed. The Company will apply to regulatory authorities for appropriate clearances, as required. Chattem is registered with the US Drug

Full Post: Sun Pharma acquires Chattem Chemicals, Inc